Mablink Bioscience SAS., Université Claude Bernard Lyon 1 and Centre National de la Recherche Scientifique have patented antibody-drug conjugates consisting of antibodies covalently linked to therapeutic drugs through an enzyme-triggered self-immolative linker reported to be useful for the treatment of cancer.